1996
Oncology
DeVita V, Deisseroth A. Oncology. JAMA 1996, 275: 1833-1834. PMID: 8642736, DOI: 10.1001/jama.1996.03530470061036.Peer-Reviewed Original Research
1995
The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents.
Deisseroth A, DeVita V. The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents. The Cancer Journal 1995, 1: 15-21. PMID: 9166447.Peer-Reviewed Original ResearchConceptsMolecular determinants of resistanceNormal tissuesSensitivity to cytotoxic agentsConventional dose therapyTherapy-induced side effectsIntroduction of chemotherapyCurative therapeutic interventionParadigm of treatmentPresence of mutationsCells to treatmentDose therapyBiologic therapySolid tumorsDeterminants of resistanceHematopoietic neoplasmsChemotherapeutic agentsChemotherapyCytotoxic agentsNeoplastic cellsSide effectsTherapyApplication of molecular analysisTherapeutic interventionsCell deathNeoplasms
1989
NCI's breast cancer clinical alert: rationale and results.
DeVita V, Hubbard S. NCI's breast cancer clinical alert: rationale and results. Resident & Staff Physician 1989, 35: 49-55. PMID: 10303742.Peer-Reviewed Original Research
1988
Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities.
Whang-Peng J, Young R, Lee E, Longo D, Schechter G, DeVita V. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988, 71: 403-14. PMID: 3337904, DOI: 10.1182/blood.v71.2.403.bloodjournal712403.Peer-Reviewed Original ResearchConceptsChromosomal abnormalitiesStructural abnormalitiesLoss of chromosome 7Cytogenetic studiesDe novo leukemiaCytogenetic abnormalitiesRadiation therapyExtensive chemotherapyNumerical abnormalitiesTreatment modalitiesSerial studiesChemotherapyPatientsAbnormalitiesTreatment groupsHematological changesChromosome 7SyndromeTreatmentChromosome 3HypodiploidyLeukemiaAneuploidyTherapyCytogenetic Studies in Patients With Secondary Leukemia/Dysmyelopoietic Syndrome After Different Treatment Modalities
Whang-Peng J, Young R, Lee E, Longo D, Schechter G, DeVita V. Cytogenetic Studies in Patients With Secondary Leukemia/Dysmyelopoietic Syndrome After Different Treatment Modalities. Blood 1988, 71: 403-414. DOI: 10.1182/blood.v71.2.403.403.Peer-Reviewed Original ResearchCytogenetic studiesChromosomal abnormalitiesStructural abnormalitiesLoss of chromosome 7De novo leukemiaAbstract Cytogenetic studiesCytogenetic abnormalitiesRadiation therapyExtensive chemotherapyNumerical abnormalitiesTreatment modalitiesSerial studiesChemotherapyPatientsAbnormalitiesTreatment groupsHematological changesChromosome 7SyndromeTreatmentChromosome 3HypodiploidyLeukemiaAneuploidyTherapy
1987
The evolution of chemotherapy of lymphomas of adults.
DeVita V. The evolution of chemotherapy of lymphomas of adults. Leukemia 1987, 1: 467-85. PMID: 3312842.Peer-Reviewed Original Research
1986
The effect of combined modality therapy on local control and survival
DeVita V, Lippman M, Hubbard S, Ihde D, Rosenberg S. The effect of combined modality therapy on local control and survival. International Journal Of Radiation Oncology • Biology • Physics 1986, 12: 487-501. PMID: 3009367, DOI: 10.1016/0360-3016(86)90056-8.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsAnus NeoplasmsBreast NeoplasmsCarcinoma, Small CellClinical Trials as TopicCombined Modality TherapyFemaleHumansKidney NeoplasmsLung NeoplasmsLymphomaNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasmsPrognosisSarcomaSoft Tissue NeoplasmsWilms TumorConceptsLocal controlSystemic treatmentTumor typesPresence of micrometastasesEffective systemic therapyTumor cell numberLocal control measuresModality therapySystemic therapyCommon cancerMetastatic cancerLESS surgeryRadiation therapyTherapeutic programMetastatic processMicrometastasesTherapySurvivalSystemic componentCell numberTumorsMetastasis genesCancerSubstantial numberInverse relationship
1985
Current Management of Hodgkin’s Disease
Behrens B, Young R, DeVita V. Current Management of Hodgkin’s Disease. Drugs 1985, 30: 355-367. PMID: 3905335, DOI: 10.2165/00003495-198530040-00004.Peer-Reviewed Original ResearchConceptsComplete remissionHodgkin's diseaseDurable complete remissionAcute side effectsCombination chemotherapy programsLong-term complicationsPrognosis of patientsImproved treatment approachesProbable cureInduction therapySalvage therapyMost patientsTerm complicationsChemotherapy programSuch patientsStandard radiotherapySpecific therapySide effectsTreatment approachesPatientsCurrent managementCurrent trialDiseaseTherapyRemissionThe current status of NCI trials in Hodgkin’s disease
Young R, Longo D, Glatstein E, Duffey P, Winkler C, Wiernik P, Devita V. The current status of NCI trials in Hodgkin’s disease. Developments In Oncology 1985, 293-298. DOI: 10.1007/978-1-4613-2607-6_30.Peer-Reviewed Original Research
1983
Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma.
Greene M, Young R, Merrill J, DeVita V. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Research 1983, 43: 1891-8. PMID: 6572558.Peer-Reviewed Original ResearchConceptsRisk of acute nonlymphocytic leukemiaNon-Hodgkin's lymphomaAcute nonlymphocytic leukemiaCases of acute nonlymphocytic leukemiaNonlymphocytic leukemiaTherapy of non-Hodgkin's lymphomaNon-Hodgkin lymphoma cohortNon-Hodgkin's lymphoma patientsSingle-modality therapyModel of leukemogenesisCase-control studyCumulative radiation dosePatients per yearOptimum patient managementHemibody radiationLeukemogenic therapyNational Cancer InstituteChemotherapy durationHistological subtypesChemotherapy doseTreatment regimensBone marrowTotal bodyPatient managementTherapy
1980
General Progress in Clinical Chemotherapy of Advanced Disease
Muggia F, Henney J, DeVita V. General Progress in Clinical Chemotherapy of Advanced Disease. Recent Results In Cancer Research 1980, 74: 1-7. PMID: 7003657, DOI: 10.1007/978-3-642-81488-4_1.Peer-Reviewed Original ResearchConceptsAggressive systemic treatmentMinimal residual diseaseTumor cell cytotoxicityAdvanced diseaseImmunologic factorsSystemic treatmentLocal therapyAdvanced cancerTumor burdenResidual diseaseTumor controlCurative approachLocoregional drug deliveryClinical chemotherapySuccessful chemotherapyEffective drugsDrug pharmacologyCell cytotoxicityInfectious diseasesDiseaseChemotherapyCancerCurrent resultsCellular heterogeneityTherapy
1979
Human models of human diseases; breast cancer and the lymphomas
Devita V. Human models of human diseases; breast cancer and the lymphomas. International Journal Of Radiation Oncology • Biology • Physics 1979, 5: 1855-1867. PMID: 393666, DOI: 10.1016/0360-3016(79)90571-6.Peer-Reviewed Original ResearchTreatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion.
Canellos G, Sutliffe S, DeVita V, Lister T. Treatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion. Blood 1979, 53: 1014-7. PMID: 435637, DOI: 10.1182/blood.v53.5.1014.bloodjournal5351014.Peer-Reviewed Original ResearchConceptsSplenic artery infusionArterial infusionBlastic phase of chronic granulocytic leukemiaRefractory to previous therapyPhase of chronic granulocytic leukemiaChronic granulocytic leukemiaResponse to treatmentBlastic phasePrevious therapyMassive splenomegalyMyeloproliferative diseaseSystemic toxicityGranulocytic leukemiaSpleen sizeSymptomatic reliefCytosine arabinosidePatientsSplenomegalyInfusionTreatmentHypersplenismPainLeukemiaTherapyArabinosideTreatment of Refractory Splenomegaly in Myeloproliferative Disease by Splenic Artery Infusion
Canellos G, Sutliffe S, DeVita V, Lister T. Treatment of Refractory Splenomegaly in Myeloproliferative Disease by Splenic Artery Infusion. Blood 1979, 53: 1014-1017. DOI: 10.1182/blood.v53.5.1014.1014.Peer-Reviewed Original ResearchSplenic artery infusionArterial infusionBlastic phase of chronic granulocytic leukemiaRefractory to previous therapyPhase of chronic granulocytic leukemiaChronic granulocytic leukemiaResponse to treatmentBlastic phasePrevious therapyMassive splenomegalyMyeloproliferative diseaseSystemic toxicityGranulocytic leukemiaSpleen sizeSymptomatic reliefCytosine arabinosidePatientsSplenomegalyInfusionTreatmentHypersplenismPainLeukemiaTherapyArabinoside
1978
Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma
Johnson B, Fisher R, Bender R, Devita V, Chabner B, Young R. Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma. Cancer 1978, 42: 2157-2161. PMID: 102417, DOI: 10.1002/1097-0142(197811)42:5<2157::aid-cncr2820420511>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsDose modificationOvarian cancerDiscontinuation of therapyAdvanced ovarian cancerMedian durationObjective responseAgent therapyProspective studyOvarian carcinomaDay courseSevere toxicityPatientsAttractive agentTherapyToxic effectsHexamethylmelamineCancerDegree of toxicityToxicityActive agentsDiscontinuationChemotherapyNeurologicCarcinomaHematologicPatterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy
Young R, Canellos G, Chabner B, Hubbard S, Devita V. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 1978, 42: 1001-1007. PMID: 688174, DOI: 10.1002/1097-0142(197808)42:2+<1001::aid-cncr2820420723>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsPatterns of relapseAdvanced Hodgkin's diseaseComplete remissionCombination chemotherapyHodgkin's diseasePrevious diseaseNodal sitesNodular sclerosis histologyProphylactic radiation therapyLeft supraclavicular areaSite of diseaseNodal diseaseSystemic symptomsSupraclavicular areaRadiation therapyRelapse increasesNodal areasPatientsRelapseDiseaseRemissionChemotherapyHistologyTherapyThe chemotherapy of Hodgkin's disease. Past experiences and future directions
Devita V, Lewis B, Rozencweig M, Muggia F. The chemotherapy of Hodgkin's disease. Past experiences and future directions. Cancer 1978, 42: 979-990. PMID: 356960, DOI: 10.1002/1097-0142(197808)42:2+<979::aid-cncr2820420721>3.0.co;2-s.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombination chemotherapyAntitumor response rateAdvanced Hodgkin's diseaseComplete remissionDrug therapyDrug combinationsEffective treatmentTherapeutic experimentsAntitumor effectsResponse rateChemotherapyClinical investigatorsNatural historyEffective agentDiseasePatientsMarked increaseTreatmentNitrogen mustardRemissionTherapyDiffuse histiocytic lymphoma involving the gastrointestinal tract
Hande K, Fisher R, Devita V, Chabner B, Young R. Diffuse histiocytic lymphoma involving the gastrointestinal tract. Cancer 1978, 41: 1984-1989. PMID: 348299, DOI: 10.1002/1097-0142(197805)41:5<1984::aid-cncr2820410544>3.0.co;2-8.Peer-Reviewed Original ResearchConceptsDiffuse histiocytic lymphomaBowel perforationComplete remissionSurgical resectionHistiocytic lymphomaGastrointestinal tractActive chemotherapeutic regimensMassive intestinal hemorrhageMajority of patientsResults of stagingRigorous stagingGastrointestinal lymphomaSystemic chemotherapySystemic therapyBowel lesionsChemotherapeutic regimensIntestinal hemorrhageDrug therapyRadiation therapyPatientsTumor resistanceLymphomaTherapyRelative rarityWidespread disease
1977
The treatment of Hodgkin's disease
Young R, Anderson T, DeVita V. The treatment of Hodgkin's disease. Current Problems In Cancer 1977, 1: 1-29. PMID: 66119, DOI: 10.1016/s0147-0272(77)80009-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultBleomycinBone MarrowChildClinical Trials as TopicDrug Therapy, CombinationFemaleHodgkin DiseaseHumansLaparoscopyLaparotomyLiverLymph NodesMaleMechlorethamineNational Institutes of Health (U.S.)Neoplasms, Multiple PrimaryPrednisoneProcarbazineRadiotherapy, High-EnergySpleenSplenectomyUnited StatesVincristine
1976
Treatment of hodgkin's disease using intensive chemotherapy followed by irradiation
Kun L, Devita V, Young R, Johnson R. Treatment of hodgkin's disease using intensive chemotherapy followed by irradiation. International Journal Of Radiation Oncology • Biology • Physics 1976, 1: 619-626. PMID: 824248, DOI: 10.1016/0360-3016(76)90143-7.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseResidual Hodgkin's diseaseTreatment-related morbidityUntreated Hodgkin's diseaseNormal tissue reactionsIntensive chemotherapyMarginal recurrenceCombination chemotherapyIncreased incidenceAutopsy examinationRadiation therapyTherapeutic efficacyFull doseMedical CollegeDiseasePatientsTissue reactionChemotherapyMarked enhancementIrradiation fieldMorbidityComplicationsRecurrenceTherapyIncidence